New Canadian Patent



    DENVER, CO, June 11 /CNW Telbec/ - Medical International Technology Inc.
(MDLH. PK) (http://www.mitcanada.ca http://www.mitinvest.ca), "MIT" is pleased
to announce that it has received a Canadian Patent for its Needle-Free
Jet-Injector and has passed its yearly ISO continuing assessment Audit.

    Canadian patent

    "MIT" is pleased to announce that it has obtained another Canadian patent
from the Canadian Patent and Trademark Office for its Needle-Free
Jet-Injector. Other similar international patents are pending. This patent
will help the company expand into the world market reinforcing the validity
and recognition of our technology. This technology offers a front-line means
of prevention against pandemics, contributes to eliminate the possibility of
both pre-injection contamination and post-injection cross-infection from
needles/syringes, increases institutional sanitation, and protects human
health.

    ISO Audit

    MIT recently successfully underwent a continuing assessment audit
ensuring continued suitability of our Quality Management System, in accordance
with MDD93/42/EEC for the European Union, ISO 9001:2000 and ISO 13485:2003
including certification for the "Canadian Medical Device Conformity Assessment
System" (CMDCAS) for devices licensed by HEALTH CANADA.

    Hazards Of The Traditional Needle

    The MED-JET provides more safety than the traditional needle. According
to the International Sharps Injury Prevention Society (http://www.isips.org),
it has been estimated that a contaminated sharp point accidentally sticks one
out of every seven workers every year. Every day over 2,100 health care
professionals will incur a needlestick related injury. More than 20 types of
infectious agents have been transmitted through needlesticks, including
hepatitis B and C, tuberculosis, syphilis, malaria, herpes, diphtheria,
gonorrhea, typhus and Rocky Mountain spotted fever. The MED-JET will eliminate
this risk to all health care professionals around the world and create a safer
workplace.
    MIT has marketed its MED-JET for human use for mass-inoculation. With the
recent outbreak of the "swine-flu" H1-N1 and the increased fear of the
possible pandemic that could affect and kill millions of people around the
world, our company feels that Canadian and other world markets will benefit
greatly from MIT's unique needle-free technology. By using the MED-JET, health
officials around the world have a delivery method that is safer and faster
than the traditional needle.
    Medical International Technology Inc. is pleased to continue providing a
safe and effective means to help prevent the spread of deadly diseases to both
humans and animals through the use of the Med-Jet(R) and Agro-Jet(R)
needle-free injection system.

    
    Karim Menassa, President
    On Behalf of the Board of Directors                    Tel: 514-339-9355
    

    About Medical International Technology, Inc. MIT CANADA, with offices in
Montreal, is a subsidiary of Denver, Colorado-based Medical International
Technology, Inc. (MIT USA), which specializes in the development, production,
marketing and sale of needle-free injectors both for humans and animals, for
individual and mass vaccinations.

    The statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties, including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development and acquisition of new product lines and services, government
approval processes, the impact of competitive products or pricing a
technological changes, the effect of economic conditions and other
uncertainties, and the risk factors set forth from time to time in the
Company's SEC reports, including but not limited to its annual report on Form
10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K.
Medical International Technology Inc. takes no obligation to update or correct
forward-looking statements.




For further information:

For further information: Karim Menassa, President & CEO, (514) 339-9355,
k.menassa@mitcanada.ca; www.mitcanada.ca; pr@mitcanada.ca

Organization Profile

MEDICAL INTERNATIONAL TECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890